FDA Announces Draft Guidance on Waivers for HIV Treatment Drugs

Summary

The FDA is releasing a draft guidance outlining circumstances under which companies may be eligible for a waiver of user fees for new drug applications for HIV treatment drugs, as part of the President's Emergency Plan for AIDS Relief.